Market revenue in 2023 | USD 2,154.4 million |
Market revenue in 2030 | USD 3,389.5 million |
Growth rate | 6.7% (CAGR from 2023 to 2030) |
Largest segment | Traditional active pharmaceutical ingredient (traditional api) |
Fastest growing segment | Antibody Drug Conjugate (ADC |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Traditional Active Pharmaceutical Ingredient (Traditional API), Highly Potent Active Pharmaceutical Ingredient (HP-API), Antibody Drug Conjugate (ADC |
Key market players worldwide | Recipharm, Thermo Fisher Scientific Inc, Samsung BioLogics, Lonza Group Ltd, Catalent Inc, Siegfried Holding AG, Piramal Pharma Solutions, Boehringer Ingelheim, Cambrex, CordenPharma |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to active pharmaceutical ingredient cdmo market will help companies and investors design strategic landscapes.
Traditional active pharmaceutical ingredient (traditional api) was the largest segment with a revenue share of 41.13% in 2023. Horizon Databook has segmented the Argentina active pharmaceutical ingredient cdmo market based on traditional active pharmaceutical ingredient (traditional api), highly potent active pharmaceutical ingredient (hp-api), antibody drug conjugate (adc covering the revenue growth of each sub-segment from 2018 to 2030.
Argentina accounted for 12.3% of Latin America’s market in 2020. Argentina is one of the most advanced Latin American countries in terms of regulatory legislations. It is a lucrative market for API contract development and manufacturing, owing to its favorable regulatory guidelines, cost compliance, and established clinical & manufacturing infrastructure.
Over the coming years, biotechnology and pharmaceutical companies may begin outsourcing API CDMO activities to Argentina to take advantage of its cost-effectiveness, time-saving, specialized expertise, coupled with presence of international standards compliance such as the Good Clinical Practices & Good Manufacturing Practices.
Such factors are expected to boost market growth in the country. Growing number of clinical trials in the country is projected to create opportunities for active pharmaceutical ingredient CDMOs. According to WHO ICTRP, 6,480 clinical trials were conducted in Argentina between 1999 and 2020.
Horizon Databook provides a detailed overview of country-level data and insights on the Argentina active pharmaceutical ingredient cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Argentina active pharmaceutical ingredient cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account